Abstract
<h3>Introduction</h3> Protein losing enteropathy (PLE) is one of the main reasons for heart transplant referral in patients with a Fontan circulation PLE develops in 1-10% of Fontan patients and has a 5 year mortality rate as high as 50%. The largest contemporary cohort of Fontan patients with PLE who underwent heart transplantation, showed a 1 year survival rate of 83%. Of those that survived, 98% of patients had resolution of PLE. <h3>Case Report</h3> A 25 year old woman underwent orthotopic heart transplantation in May 2019 for advanced heart failure secondary to a failing Fontan Circulation and PLE. Biweekly paracentesis was used pre-transplant for the management of refractory ascites. Post-transplant, her ascites improved and as of Feb 2020, she no longer required paracentesis. In April 2020, prednisone was discontinued (lack of rejection). In June 2020, she developed CMV enteritis (PCR of 1.2 × 10<sup>6</sup> IU/mL from previous negative). Abdominal ultrasound showed recurrence of large volume ascites. She received IV ganciclovir. Fibroscan liver stiffness was 9 kPa (vs 21 kPa pre-transplant), excluding cirrhosis. Stool alpha-1-antitrypsin clearance/24 hours was 268mL, consistent with PLE. Paracentesis (Aug 2020) showed: Ascites albumin 6, Serum albumin 22, SAAG of 1.6g/dL (vs 1.2g/dL pre-transplant), consistent with elevated portal pressures. Prednisone (5mg) and spironolactone (25mg) were restarted, and furosemide (160mg) was up-titrated, with signs of clinical improvement. <h3>Summary</h3> To the authors' knowledge, this is the first reported case of recurrent PLE post heart transplantation in the context of CMV-enteritis. Two major mechanisms are hypothesized: invasion and injury of the endothelial cells by CMV plus an increase in vascular permeability. The patient's ascites is improving with prednisone, spironolactone and furosemide. The authors hypothesize that this recurrence of PLE will resolve given treatment of the underlying precipitant (CMV) and the high rates of resolution described in the literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
